Hangzhou Tigermed
A contract research company providing whole process clinical trial services for the R&D of pharmaceuticals.
Market cap
$6.0b
Enterprise value
$6.2b
Share price
CNY53.59 300347.SZ
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | N/A | IPO | |
| Total Funding | 000k | ||
Qiming Venture Partners(exited)
| CNY | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 63 % | 36 % | 4 % | (11 %) | 8 % | 13 % | 9 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 40 % | 34 % | 36 % | 25 % | 22 % | 23 % | 28 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 55 % | 28 % | 27 % | 6 % | 15 % | 19 % | 19 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 4 % | 3 % | 4 % | 4 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
exited
exited
ACQUISITION by Tigermed Oct 2015
ACQUISITION by Hangzhou Tigermed Jul 2024
exited